Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors That Address Undruggable Diseases
Company emerges as key player creating exotic and difficult-to-express proteins (DTEPs) as a biomanufacturing partner for protein AI companies and a vendor to the four trillion dollar syn-bio industry
EDMONTON, Alberta – June 17, 2025 – Future Fields, the protein biomanufacturing company behind the world’s first Drosophila-based EntoEngine™ platform and Instar biofactory, today announced the close of its Series A funding round to expand the company’s commercial traction across agriculture, food, and biopharma markets. The $8.0 million USD oversubscribed round was co-led by Amplify Capital, Business Development Bank of Canada (BDC)’s Climate Tech Fund, and R7 Partners, and signals robust investor interest for the company’s unique ability to produce critical, challenging proteins at low cost and with low climate impact. Partners from each of the venture firms leading the round will join Future Field’s board, including Pascal Lanctot of BDC’s Climate Tech Fund, Kathryn Wortsman of Amplify Capital; and Trey Ward of R7 Partners. The funds will be used to expand its operational capacity to produce bioproducts and next-generation medicines, helping overcome the shortage and technical capacity of bioreactors underlying the four trillion dollar syn-bio industry.
“It’s important to remember that our technology doesn’t just mean the ability to create new types of drugs and proteins,” said Matt Anderson-Baron, CEO and cofounder of Future Fields. “This round attracted a number of marquee venture firms who recognize both the market opportunity and the ethical necessity in creating a sustainable and climate-resilient biomanufacturing infrastructure.”
Proteins are a fundamental structure essential to the basic functioning of a multi-trillion swath of industries spanning biopharmaceuticals, medicine, and more. But even before artificial intelligence was inventing new proteins that could potentially treat undruggable diseases like Alzheimer’s, the status quo approach to their creation was failing to supply industry demands. With geopolitical tensions increasing the need for domestic suppliers of these critical materials, Future Fields is emerging as a key player that recently opened its first commercial facility in December 2024 to scale production for clients that include agricultural leaders, food innovators, and biopharma companies making therapies for cancer and immune disorders.
While conventional approaches use steel tanks propagating cells like Chinese Hamster Ovaries or bacteria like E. coli, Future Fields’ proprietary EntoEngine™ turns transgenic fruit flies into biofactories. The approach unlocks orders of magnitude gains in cost and scale while reducing its environmental footprint. Having started first with conventional proteins, the new funding will now power the company’s platform expansion to create proteins inside exotic tissues such as neurons, muscle cells, and more, to enable next generation disease research. The news is a significant step forward for the industry’s ability to manufacture new proteins for undruggable and intractable diseases as well as those being designed by AI companies. As part of the news, Future Fields is announcing a partnership with Protein Evolution, to produce AI-engineered proteins.
The round includes a number of notable venture capitalists and sustainable funders. Amplify Capital increased their equity stake from the previous round, while BDC Climate Tech Fund and R7 Partners bring an additional wealth of knowledge in solutions to improve life on earth. A number of existing investors joined the round, including returning Toyota Ventures, BoxOne Ventures, and Builders VC, and new funders TRAC VC and University of Alberta Innovation Fund.
“Future Fields stands out as a strong choice in our industrial decarbonization focus and has continued to meet milestones from the Series Seed round. Now a technology platform Company with multiple use cases, Future Fields has demonstrated the ability to disrupt traditional biomanufacturing processes to reduce carbon footprint, capital costs, increase quality, supply stability, and improve manufacturing efficiency.”
— Kathryn Wortsman, Managing Partner at Amplify Capital
“Future Fields’ technology is a game changer. It brings about a new way of manufacturing proteins at a much lower cost and GHG footprint. Its bioreactors have an important impact on the climate by shrinking the energy consumption, material usage and waste output of an entire industry. It’s exactly the type of impactful, innovative company that BDC and its Climate Tech Fund want to invest in and work with to see them grow.”
— Pascal Lanctot, Partner at BDC’s Climate Tech Fund
“We believe that Future Fields will be a key breakthrough in biomanufacturing to support both the creation of new proteins and bridge the massive supply gap that exists already.”
— Trey Ward, General Partner at R7 Partners
Future Fields is a fly biotechnology company based in Edmonton, Canada.
Founded in 2018, Future Fields is on a mission to change how we do science for humanity and the planet.
Our biomanufacturing platform, the EntoEngine™, is the first synthetic biology system in the world to use fruit flies for recombinant protein production. Powered by people and fly by design, we’re equipping industries with the biomolecular tools they need to sustainably, ethically, and economically conduct great science.
As of 2023, our lab has been Green-certified by My Green Lab, and our FGF2 are the first growth factors in the world to receive the ACT Environmental Impact Factor Label. Future Fields is a proud business member of 1% for the Planet and the United Nations Global Compact initiative. Learn more about how we’re transforming science at futurefields.io.